Advice
in the absence of a submission from the holder of the marketing authorisation:
sirolimus (Rapamune®) is not recommended for use within NHSScotland.
Indication under review: treatment of patients with sporadic lymphangioleiomyomatosis with moderate lung disease or declining lung function. The holder of the marketing authorisation has not made a submission to SMC regarding this product in this indication. As a result we cannot recommend its use within NHSScotland.
Download detailed advice355KB (PDF)
Medicine details
- Medicine name:
- sirolimus (Rapamune)
- SMC ID:
- SMC2173
- Indication:
- Treatment of patients with sporadic lymphangioleiomyomatosis with moderate lung disease or declining lung function.
- Pharmaceutical company
- Pfizer Ltd
- BNF chapter
- Respiratory system
- Submission type
- Non submission
- Status
- Not recommended
- Date advice published
- 08 October 2018